Skip to main content
Advertisement
  • Neurology.org
  • Journals
    • Neurology
    • Clinical Practice
    • Genetics
    • Neuroimmunology & Neuroinflammation
    • Education
  • Online Sections
    • Neurology Video Journal Club
    • Inclusion, Diversity, Equity, Anti-racism, & Social Justice (IDEAS)
    • Innovations in Care Delivery
    • Practice Buzz
    • Practice Current
    • Residents & Fellows
    • Without Borders
  • Collections
    • COVID-19
    • Disputes & Debates
    • Health Disparities
    • Infographics
    • Null Hypothesis
    • Patient Pages
    • Topics A-Z
    • Translations
  • Podcast
  • CME
  • About
    • About the Journals
    • Contact Us
    • Editorial Board
  • Authors
    • Submit a Manuscript
    • Author Center

Advanced Search

Main menu

  • Neurology.org
  • Journals
    • Neurology
    • Clinical Practice
    • Genetics
    • Neuroimmunology & Neuroinflammation
    • Education
  • Online Sections
    • Neurology Video Journal Club
    • Inclusion, Diversity, Equity, Anti-racism, & Social Justice (IDEAS)
    • Innovations in Care Delivery
    • Practice Buzz
    • Practice Current
    • Residents & Fellows
    • Without Borders
  • Collections
    • COVID-19
    • Disputes & Debates
    • Health Disparities
    • Infographics
    • Null Hypothesis
    • Patient Pages
    • Topics A-Z
    • Translations
  • Podcast
  • CME
  • About
    • About the Journals
    • Contact Us
    • Editorial Board
  • Authors
    • Submit a Manuscript
    • Author Center
  • Home
  • Latest Articles
  • Current Issue
  • Past Issues
  • Residents & Fellows

User menu

  • Subscribe
  • My Alerts
  • Log in
  • Log out

Search

  • Advanced search
Neurology
Home
The most widely read and highly cited peer-reviewed neurology journal
  • Subscribe
  • My Alerts
  • Log in
  • Log out
Site Logo
  • Home
  • Latest Articles
  • Current Issue
  • Past Issues
  • Residents & Fellows

Share

July 07, 2009; 73 (1) Articles

Sudomotor, skin vasomotor, and cardiovascular reflexes in 3 clinical forms of Lewy body disease

Y. Akaogi, M. Asahina, Y. Yamanaka, Y. Koyama, T. Hattori
First published June 29, 2009, DOI: https://doi.org/10.1212/WNL.0b013e3181aae83c
Y. Akaogi
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
M. Asahina
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Y. Yamanaka
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Y. Koyama
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
T. Hattori
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Full PDF
Citation
Sudomotor, skin vasomotor, and cardiovascular reflexes in 3 clinical forms of Lewy body disease
Y. Akaogi, M. Asahina, Y. Yamanaka, Y. Koyama, T. Hattori
Neurology Jul 2009, 73 (1) 59-65; DOI: 10.1212/WNL.0b013e3181aae83c

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Permissions

Make Comment

See Comments

Downloads
394

Share

  • Article
  • Figures & Data
  • Info & Disclosures
Loading

Abstract

Objective: To elucidate the differences among dementia with Lewy bodies (DLB), Parkinson disease with dementia (PDD), and Parkinson disease without dementia (PD), with respect to the involvement of the autonomic nervous system, we clinically investigated the cutaneous and cardiovascular autonomic functions in patients with Lewy body disease.

Methods: We studied 36 patients with Lewy body disorders, including 12 patients with DLB (age, 75.4 ± 5.9 years), 12 patients with PDD (71.0 ± 6.8 years), and 12 patients with PD (70.9 ± 4.2 years), and 12 healthy control subjects (69.9 ± 5.3 years). Sympathetic sweat response (SSwR) and skin vasomotor reflex (SkVR) on the palm were recorded to estimate the cutaneous sympathetic function, and the head-up tilt test was performed and coefficient of variation of R-R intervals (CVR-R) was studied to estimate the cardiovascular function.

Results: The patients with DLB, patients with PDD, and patients with PD showed severely reduced SSwR amplitudes, significantly lower than that in the controls. The mean SkVR amplitudes in the patients with DLB and patients with PDD were significantly lower than that in the controls, but not in the patients with PD. The mean decreases in the systolic blood pressure during the head-up tilt test in the patients with DLB and patients with PDD were less than that in the controls. The mean CVR-R value was significantly lower in the patients with DLB.

Conclusion: Sudomotor function on the palm may be severely affected in Lewy body disorders, while skin vasomotor function and the cardiovascular system may be more severely affected in dementia with Lewy bodies and Parkinson disease with dementia than in Parkinson disease.

Glossary

ANOVA=
analysis of variance;
CVR-R=
coefficient of variation of R-R intervals;
DLB=
dementia with Lewy bodies;
LBD=
Lewy body disease;
PD=
Parkinson disease;
PDD=
Parkinson disease with dementia;
SkVR=
skin vasomotor reflex;
SSwR=
sympathetic sweat response.

Lewy body disease (LBD), which is characterized by the presence of Lewy bodies in the nervous system, represents several clinical forms, such as Parkinson disease without dementia (PD), Parkinson disease with dementia (PDD), dementia with Lewy bodies (DLB), and pure autonomic failure.1–3 With regard to the pathologic staging of PD, a 6-stage system has been suggested to indicate a predictable sequence of lesions with ascending progression from the medullary (the dorsal motor nucleus of the glossopharyngeal and vagal nerves) and olfactory nuclei to the cortex. The first 2 presymptomatic stages are related to incidental LBD, stages 3 and 4 with motor symptoms, while the last 2 (cortical) stages may be frequently associated with cognitive impairment.1,4 Although there has been a controversy as to whether the different clinical forms of LBD have similar cerebral Lewy body pathology, autonomic failure may clinically precede other neurologic features in LBD5,6 as well as olfactory dysfunction.1 On the other hand, the severity of cardiovascular autonomic dysfunction may be more severe in DLB/PDD than in PD.7–9 However, differences in other autonomic dysfunctions, such as cardiac parasympathetic, sudomotor, and skin vasomotor dysfunctions, between DLB/PDD and PD have not been well investigated.

In PD, Lewy bodies are distributed in the hypothalamus, intermediolateral nucleus, sympathetic ganglia, dorsal vagal nucleus, and sacral parasympathetic nucleus.10 It is suggested that the lesions initially occur in the dorsal vagal and olfactory nucleus and progress to the substantia nigra, finally reaching the neocortical areas in PD.4 Lewy bodies may initially occur in the sympathetic ganglia, intermediolateral nucleus, and intramural ganglia.11 These hypotheses have not been clinically well proven, although several studies using 123I-MIBG scintigraphy indicated that cardiac sympathetic denervation occurs in early stage PD.12

In DLB, neuronal loss in the raphe nucleus, ventrolateral medulla, dorsal vagal nucleus, and locus ceruleus manifest as lesions in the central autonomic nervous system.13 Cardiac sympathetic denervation may occur in early stage DLB14 as well as PD. However, where Lewy body pathology begins and how it develops in DLB is currently unclear. Lewy body pathology in DLB may begin from dorsal vagal nucleus and olfactory nucleus or cardiac sympathetic neurons similar to PD, or progress in a manner different from PD.15

METHODS

Subjects.

Participants included 36 patients with Lewy body disorders, including 12 with DLB (mean age 75.4 ± 5.9 years, 10 men and 2 women), 12 with PDD (mean age 71.0 ± 6.8 years, 7 men and 5 women), and 12 with PD (mean age 70.9 ± 4.2 years, 4 men and 8 women) (table). The diagnosis of DLB was established according to the consensus criteria for dementia with Lewy bodies.2 The patients with PD satisfied the criteria of the United Kingdom Brain Bank,16 and did not have dementia. Patients with PDD met both the criteria of the United Kingdom Brain Bank16 and DLB consensus criteria,2 with motor disorder preceding dementia by at least 12 months. Clinical profiles of patients with DLB, patients with PDD, and patients with PD are listed in the table.

View this table:
  • View inline
  • View popup
  • Download powerpoint

Table Characteristics of the patients and controls

At baseline, none of the patients was taking anticholinergic drugs. Among the patients with DLB, 5 were being treated with levodopa with decarboxylase inhibitor (Neodopaston, Daiichi Sankyo Co., Ltd., Tokyo, Japan; EC-Doparl, Kyowa Hakko Kirin Co., Ltd., Tokyo, Japan; and Madopar, Chugai Pharmaceutical Co., Ltd., Tokyo, Japan) (280 ± 40 mg/day) alone and 3 with levodopa with decarboxylase inhibitor (300 ± 100 mg/day) in combination with a dopamine agonist (cabergoline [Cabaser, Pfizer Inc., New York, NY] 2 mg/day, n = 1); selegiline (FP, FP Pharmaceutical Co., Osaka, Japan) (2.5 mg/day, n = 1); or amantadine hydrochloride (Symmetrel, Novartis Pharma, Basel, Switzerland) (100 mg/day, n = 1); 4 patients were not taking any medications. Among the patients with PDD, 10 were taking levodopa with decarboxylase inhibitor (370 ± 150 mg/day) in combination with a dopamine agonist (pergolide [Permax, Eli Lilly and Co., Indianapolis, IN] 880 ± 180 mg/day, n = 2; cabergoline 1.1 ± 0.9 mg, n = 3; bromocriptine [Parlodel, Novartis Pharma] 8.8 ± 1.8 mg, n = 2), selegiline (5.0 ± 2.0 mg/day, n = 4), amantadine hydrochloride (120 ± 30 mg/day, n = 3), or droxidopa (Dops, Dainippon Sumitomo Pharma Co., Ltd., Osaka, Japan) (300 mg/day, n = 4); 2 were not taking any medications. Among the patients with PD, one patient was being treated with levodopa (Dopasol, Daiichi Sankyo Co., Ltd.) (400 mg) alone, 2 with levodopa with decarboxylase inhibitor (300 ± 100 mg/day) alone, and 1 with cabergoline (0.25 mg/day) alone. Four patients were taking levodopa with decarboxylase inhibitor (380 ± 50 mg/day) in combination with a dopamine agonist (pergolide 830 ± 100 mg/day, n = 2; bromocriptine 7.5 mg, n = 2; pramipexole [BI Sifrol, Boehringer Ingelheim GmbH, Ingelheim, Germany] 2.8 ± 0.4 mg/day, n = 2; talipexole [Domin, Boehringer Ingelheim GmbH] 0.4 mg/day, n = 1), selegiline (2.5 mg/day, n = 2), amantadine hydrochloride (200 mg/day, n = 1), or droxidopa (250 ± 70 mg/day, n = 2); 4 patients were not taking any medications.

Age-matched healthy volunteers (mean age, 69.9 ± 5.3 years; 9 men and 3 women) comprised the control group. None of them had any neurologic disorders or clinically significant illness potentially affecting the autonomic nervous function.

Informed consent was obtained from all participants. The ethics committee of Chiba University School of Medicine reviewed the protocol.

Autonomic function tests.

The autonomic function tests were performed in a quiet room at an ambient temperature of 22-24° C. Each subject was asked to relax, stay awake, and remain in a supine position for at least 15 minutes before each test.

As indexes of cutaneous sympathetic function, sympathetic sweat response and skin vasomotor reflex were recorded.17 Sweat output was measured on the tip of the thumb (palm side) by a sudorometer (SKD-1000, Skinos, Nagano, Japan), and cutaneous blood flow was recorded at the tip of an index finger (palm side) by a Doppler flowmeter (ALF21D, Advance, Tokyo, Japan) during a sympathetic activation procedure that included deep inspiration, mental arithmetic, exercise (raising both lower limbs at 30° for 10 seconds), and tactile sensation (patient’s finger was rubbed by the examiner for 15 seconds). Figure 1 shows sweat output and cutaneous blood flow measurements in a healthy control subject. The sympathetic activation procedure increased sweat output (SSwR) and reduced cutaneous blood flow (SkVR). The SSwR amplitude was measured from the baseline to the peak, and the SkVR reduction rate (SkVR amplitude) was calculated as the percentage of reduced blood flow to basal blood flow [ (reduced flow/basal flow) × 100%]. SSwRs and SkVRs were considered absent when no responses were observed for any sympathetic activation tests. In normal controls, tactile sensation did not evoke SkVRs, and this factor was not considered when evaluating SkVRs.

Figure
  • Download figure
  • Open in new tab
  • Download powerpoint

Figure 1 Recording of sympathetic sweat response (upper) and skin vasomotor reflex (lower) in a normal control subject (man, 67 years old)

Sweat output transiently increases and skin blood flow transiently decreases, while cutaneous blood flow is reduced, in response to the sympathetic activation procedures, including deep inspiration (DI), mental arithmetic (MA), exercise (Ex), and tactile sensation (TS).

The head-up tilt test was also performed. Blood pressure and heart rate were measured by a sphygmomanometer at 1-minute intervals. After 5 minutes of baseline measurement, each subject was passively tilted on an electrically driven tilt table at 70° for 10 minutes. We diagnosed orthostatic hypotension when patients showed a reduction in systolic blood pressure of at least 20 mm Hg or diastolic blood pressure of at least 10 mm Hg within 3 minutes of standing.

For evaluating the heart rate variability, electrocardiography was performed with the subjects in a supine position as 3 series of 100 consecutive R-R intervals with an accuracy of 1 msec during normal breathing in each subject. As an index of heart rate variability, the coefficient of variation of R-R intervals (CVR-R) was calculated as the SD divided by the mean R-R interval. The average of the 3 series was used as the CVR-R value. The abnormality of a CVR-R value was judged according to age-dependent values (>1.18%; normal range in our laboratory).

Statistical analysis.

Analysis of variance (ANOVA) was used to analyze differences in parametric values among the 4 groups or 3 disorder groups. When ANOVA showed any significant difference, Tukey test was performed. Comparison of the Hoehn & Yahr stage among the 3 disorder groups was analyzed by Kruskal-Wallis test.

RESULTS

There were no significant differences in age, disease duration, or Hoehn & Yahr stage among the DLB, PDD, and PD groups (table). The basal sweat output did not differ among the 4 groups (table). All controls subjects demonstrated SSwRs. Seven patients with DLB (58.3%), 6 patients with PDD (50.0%), and 3 patients with PD (25.0%) showed absence of SSwRs for any sympathetic activation procedures. Figure 2 shows mean SSwR amplitudes in the 4 groups. The SSwR amplitudes in the patients with DLB were lower than those in the controls for deep inspiration (p < 0.001), mental arithmetic (p < 0.0005), exercise (p < 0.0005), and tactile sensation (p < 0.0005). The SSwR amplitudes in the patients with PDD were lower than those in the controls for deep inspiration (p < 0.001), mental arithmetic (p < 0.0005), exercise (p < 0.0005), and tactile sensation (p < 0.0005). The SSwR amplitudes in the patients with PD were lower than those in the controls for deep inspiration (p < 0.01), mental arithmetic (p < 0.0005), exercise (p < 0.0005), and tactile sensation (p < 0.05). There were no significant differences among the 3 disorder groups for SSwR.

Figure
  • Download figure
  • Open in new tab
  • Download powerpoint

Figure 2 Mean amplitudes of SSwRs for deep inspiration (A), mental arithmetic (B), exercise (C), and tactile sensation (D)

SSwR = sympathetic sweat response; DLB = dementia with Lewy bodies; PDD = Parkinson disease with dementia; PD = Parkinson disease without dementia. *p < 0.05 compared with the controls; **p < 0.01 compared with the controls; ***p < 0.001 compared with the controls.

The basal skin blood flow measurements did not differ among the 4 groups (table). All controls and patients with PD showed SkVRs. One patient with DLB (8%) and 3 patients with PDD (19.0%) showed no SkVRs for any procedures. The mean SkVR amplitudes in the 4 groups are shown in figure 3. The SkVR amplitudes in the patients with DLB were lower than those in the controls for deep inspiration (p < 0.05) and mental arithmetic (p < 0.05). Mean values in the patients with PDD were lower for mental arithmetic (p < 0.005) and tended to be lower for deep inspiration (p = 0.06) than in the controls, while mean values for mental arithmetic tended to be lower (p = 0.05) than in the patients with PD. The SkVR amplitudes in the patients with PD were not lower than those in the controls for any procedures.

Figure
  • Download figure
  • Open in new tab
  • Download powerpoint

Figure 3 Mean reduction rates of SkVRs for deep inspiration (A), mental arithmetic (B), and exercise (C)

SkVR = skin vasomotor reflex; DLB = dementia with Lewy bodies; PDD = Parkinson disease with dementia; PD = Parkinson disease without dementia. *p < 0.05 compared with the controls; ***p < 0.001 compared with the controls.

In the head-up tilt test, systolic blood pressure and heart rate in the baseline supine position did not differ among the 4 groups. Diastolic blood pressure in the baseline supine position in the patients with DLB (p < 0.05) and patients with PDD (p < 0.05) was higher than that in the patients with PD (table).

Orthostatic hypotension was observed in 6 patients with DLB (50.0%), 8 patients with PDD (66.7%), and 3 patients with PD (25.0%). The mean decreases in systolic blood pressure during the head-up tilt test in the patients with DLB (p < 0.005) and patients with PDD (p < 0.05) were lower than in the controls. The mean decrease in diastolic blood pressure in patients with DLB was lower than that in controls (p < 0.001) or patients with PD (p < 0.01). The mean decrease in diastolic blood pressure in patients with PDD was lower than that in controls (p < 0.05). The mean change in heart rate during the head-up tilt test did not differ among the 4 groups (figure 4). Abnormally low values of CVR-R were observed in 6 patients with DLB (50%), 3 patients with PDD (25%), and 3 patients with PD (25%). The mean CVR-R value was lower in the patients with DLB (p < 0.005, figure 4).

Figure
  • Download figure
  • Open in new tab
  • Download powerpoint

Figure 4 Mean changes in systolic (A) and diastolic (B) blood pressure and heart rate changes (C) during head-up tilt testing, and mean CVR-R (D)

SBP = systolic blood pressure; DBP = diastolic blood pressure; HR = heart rate; CVRR = coefficient of variation of R-R interval; DLB = dementia with Lewy bodies; PDD = Parkinson disease with dementia; PD = Parkinson disease without dementia. *p < 0.05 compared with the controls; **p < 0.01 compared with the controls; ***p < 0.001 compared with the controls; †p < 0.01 compared with PD.

DISCUSSION

Our patients with Lewy body disorders showed prominently diminished SSwRs on the palm. This finding indicated a dysfunction of the so-called emotional sweating, which is observed on the glabrous skin of both the palm and plantar. There have been no reports on SSwR in patients with PD, except for one study,18 where SSwR amplitudes were shown to be reduced in patients with PD. Similar results have been reported in studies evaluating the sympathetic skin response,19,20 which is considered a reflection of the electrical activity of the sweat glands. However, measurements of sympathetic skin responses are not quantitative, even though these measurements reflect emotional sweating as well as SSwR, which is actually a measurement of the amount of sweating. With regard to DLB and PDD, there have been no previous reports on SSwR or sympathetic skin responses. In our patients with Lewy body disorders, impairment of SSwRs seems to have been severe, particularly in patients with DLB and patients with PDD.

Our patients with DLB and patients with PDD showed attenuated SkVRs, although the patients with PD did not show a significant reduction in SkVRs. In a previous study, patients with PD did not show marked reduction in SkVRs.18 Although there has been no report on SkVRs in DLB or PDD, our results indicate that skin vasomotor function is impaired in DLB and PDD.

In our study, frequencies of orthostatic hypotension in patients with DLB (50.0%) and patients with PDD (66.7%) were high compared with the PD group (25.0%). The decrease in blood pressure during the head-up tilt test in patients with DLB and patients with PDD was greater compared to the patients with PD. In previous studies, orthostatic hypotension was observed in 20%-50% of patients with PD,21–24 49% of patients with PDD,25 and 50%-56% of patients with DLB.7,8,25 The decrease in blood pressure during the head-up tilt test in our patients with DLB and patients with PDD was greater as compared to the patients with PD, and these results are in agreement with previous reports.8,9 Baroreceptor reflex may be more severely disturbed in DLB and PDD compared with PD.

Our patients with DLB showed reduced CVR-R values, which is an index of heart rate variability and mainly reflects cardiac parasympathetic function. Heart rate variability in PD has been reported to be normal in some studies26–28 or mildly reduced in other studies.29,30 In DLB7,25 and PDD,25 heart rate variability has been reported to be reduced, although comparisons of the heart rate variability of patients with DLB/PDD and patients with PD have not been reported thus far. Our results indicate that the cardiac parasympathetic system might be impaired in DLB.

Our patients with Lewy body disorders showed cardiovascular, skin vasomotor, and sudomotor dysfunctions. In particular, impairment of sudomotor function on the palm (so-called emotional sweating) was noticeable. Emotional sweating may be impaired in Lewy body disorders. In addition, autonomic dysfunction was more severe in patients with DLB/PDD than in patients with PD. However, the pattern and severity of autonomic impairments were not different between the patients with DLB and patients with PDD.

It has been suggested that in PD, Lewy body pathology in the autonomic nervous system begins in the brainstem, including the dorsal motor nucleus of the vagal nerves, and progresses to the neocortex.4 Our patients with PD did not exhibit prominent abnormality in heart rate variability, but our patients with DLB presented reduced heart rate variability, which may reflect the involvement of dorsal motor nucleus of the vagal nerve. On the other hand, Lewy body pathology is also observed in the raphe,13 which plays an important role in the generation of SSwR and SkVR.31 Therefore, reduced SSwR and SkVR observed in our patients with Lewy body disorders may be related to the involvement of the raphe. In addition, Lewy body pathology in PD is observed, albeit mild, in the ventrolateral medulla,13 which plays an important role in blood pressure control.

Lewy body pathology and neuronal loss in the sympathetic ganglia are observed in Lewy body disorders.32 Cardiac MIBG uptake, which reflects postganglionic sympathetic function, is reduced in patients with Lewy body disorders, and the reduction is more pronounced in patients with DLB than in those with PD.8,33 Lewy body pathology may also start in the cardiac sympathetic neurons in the early stages of PD.11,34 Sympathetic dysfunction observed in our patients with Lewy body disorders may reflect postganglionic sympathetic lesions, as well as lesions in the central autonomic nervous system.

Although Lewy body pathology in PD may begin in the brainstem and olfactory nucleus, there may be a different pattern of evolution in DLB, with some studies suggesting that cerebrocortical pathology, including the limbic and neocortical systems, predominates in DLB.15,35 In some cases, it is known that autonomic failure precedes DLB for several years.5,6 The autonomic nervous system is regulated by several cerebral regions, including the amygdala, cingulate gyrus, and the insular and frontobasal cortices.36 These limbic lesions play an important role, particularly in so-called emotional sweating,37,38 which can be clinically investigated by evaluation of SSwR37 or sympathetic skin response.39 Therefore, SSwRs were severely diminished in our patients with Lewy body pathology. In addition, the limbic system participates in cardiovascular regulation. Limbic lesions may explain the severe autonomic dysfunction in our patients with DLB/PDD.

In our study, the clinical severity was somewhat greater in the DLB and PDD groups as compared to that in the PD group, and the disease duration was shorter in the DLB as compared to the other LBD groups. Despite this, we did not find statistically significant differences among the three LBD groups. However, it is not beyond the realm of possibility that differences in disease progression affected our results.

Clinically, sudomotor dysfunction on the palm, which was severe in our patients with DLB, patients with PDD, and patients with PD, may be a sensitive predictor for LBD. Meanwhile, skin vasomotor and cardiovascular dysfunction affected the patients with DLB and patients with PDD to a greater extent when compared to the patients with PD in our study. This finding may reflect an expanded distribution of Lewy body pathology throughout the nervous system. Similarities in autonomic dysfunction between our patients with DLB and patients with PDD indicate a possible uniformity of impairment of the autonomic nervous system in DLB and PDD.

Footnotes

  • Disclosure: The authors report no disclosures.

    Received December 11, 2008. Accepted in final form April 1, 2009.

REFERENCES

  1. ↵
    Jellinger KA. A critical reappraisal of current staging of Lewy-related pathology in human brain. Acta Neuropathol 2008;116:1–16.
  2. ↵
    McKeith IG, Dickson DW, Lowe J, et al. Diagnosis and management of dementia with Lewy bodies. Third report of the DLB consortium. Neurology 2005;65:1863–1872.
    OpenUrlAbstract/FREE Full Text
  3. Marti MJ, Tolosa E, Campdelacreu J. Clinical overview of the synucleinopathies. Mov Disord 2003;18(suppl 6):S21–S27.
    OpenUrlCrossRefPubMed
  4. ↵
    Braak H, Del Tredici K, Rub U, et al. Staging of brain pathology related to sporadic Parkinson’s disease. Neurobiol Aging 2003;24:197–211.
    OpenUrlCrossRefPubMed
  5. ↵
    Yamanaka Y, Asahina M, Hiraga A, et al. Over 10 years of isolated autonomic failure preceding dementia and parkinsonism in 2 patients with Lewy body disease. Mov Disord 2007;22:595–597.
    OpenUrlCrossRefPubMed
  6. Larner AJ, Mathias CJ, Roosor MN. Autonomic failure preceding dementia with Lewy bodies. J Neurol 2000;247:229–231.
    OpenUrlCrossRefPubMed
  7. ↵
    Thaisetthawatkul P, Boeve BF, Benarroch EE, et al. Autonomic dysfunction in dementia with Lewy bodies. Neurology 2004;62:1804–1809.
    OpenUrlAbstract/FREE Full Text
  8. ↵
    Oka H, Morita M, Onouchi K, et al. Cardiovascular autonomic dysfunction in dementia with Lewy bodies and Parkinson’s disease. J Neurol Sci 2007;254:72–77.
    OpenUrlCrossRefPubMed
  9. Oka H, Yoshioka M, Morita M, et al. Reduced cardiac 123I-MIBG uptake reflects cardiac sympathetic dysfunction in Lewy body disease. Neurology 2007;69:1460–1465.
    OpenUrlAbstract/FREE Full Text
  10. ↵
    Wakabayashi K, Takahashi H. Neuropathology of autonomic nervous system in Parkinson’s disease. Eur Neurol 1997;38(suppl 2):2–7.
    OpenUrl
  11. ↵
    Bloch A, Probst A, Bissig H, Adams H, Tolnay M. α-synuclein pathology of the spinal and peripheral autonomic nervous system in neurologically unimpaired elderly subjects. Neuropathol Appl Neurobiol 2006;32:284–295.
    OpenUrlCrossRefPubMed
  12. ↵
    Orimo S, Ozawa E, Nakade S, Sugimoto T, Mizusawa H. 123I-metaiodobenzylguanidine myocardial scintigraphy in Parkinson’s disease. J Neurol Neurosurg Psychiatry 1999;67:189–194.
    OpenUrlAbstract/FREE Full Text
  13. ↵
    Benarroch EE, Schmeichel AM, Low PA, et al. Involvement of medullary regions controlling sympathetic output in Lewy body disease. Brain 2005;128:338–344.
    OpenUrlAbstract/FREE Full Text
  14. ↵
    Estorch M, Camacho V, Paredes P, et al. Cardiac 123I-metaiodobenzylguanidine imaging allows early identification of dementia with Lewy bodies during life. Eur J Nucl Med Imaging 2008;35:1636–1641.
    OpenUrl
  15. ↵
    Yamamoto R, Iseki E, Marui W, et al. Non-uniformity in the regional pattern of Lewy pathology in brains of dementia with Lewy bodies. Neuropathology 2005;25:188–194.
    OpenUrlCrossRefPubMed
  16. ↵
    Ward CD, Gibb WR. Research diagnostic criteria for Parkinson’s disease. In: Streifler MB, Korczyn AD, Melamed E, et al, eds. Advances in Neurology.
  17. ↵
    Asahina M, Kikkawa Y, Suzuki A, Hattori T. Cutaneous sympathetic function in patients with multiple system atrophy. Clin Auton Res 2003;13:91–95.
    OpenUrlCrossRefPubMed
  18. ↵
    Kikkawa Y, Asahina M, Suzuki A, Hattori T. Cutaneous sympathetic function and cardiovascular function in patients with progressive supranuclear palsy and Parkinson’s disease. Parkinsonism Relat Disord 2003;10:101–106.
    OpenUrlCrossRefPubMed
  19. ↵
    Wang SJ, Fuh JL, Shan DE, et al. Sympathetic skin response and R-R interval variation in Parkinson’s disease. Mov Disord 1993;8:151–157.
    OpenUrlCrossRefPubMed
  20. Schestatsky P, Ehlers JA, Rieder CR, Gomes I. Evaluation of sympathetic skin response in Parkinson’s disease. Parkinsonism Relat Disord 2006;12:486–491.
    OpenUrlCrossRefPubMed
  21. ↵
    Goetz CG, Lutge W, Tanner CM. Autonomic dysfunction in Parkinson’s disease. Neurology 1986;36:73–75.
    OpenUrlAbstract/FREE Full Text
  22. Goldstein DS, Holmes C, Li ST, Bruce S, Metman LV, Cannon RO 3rd. Cardiac sympathetic denervation in Parkinson disease. Ann Intern Med 2000;133:338–347.
    OpenUrlPubMed
  23. Wenning GK, Scherfler C, Granata R, et al. Time course of symptomatic orthostatic hypotension and urinary incontinence in patients with postmortem confirmed parkinsonian syndromes: a clinicopathological study. J Neurol Neurosurg Psychiatry 1999;67:620–623.
    OpenUrlAbstract/FREE Full Text
  24. Senard JM, Brefel-Courbon C, Rascol O, Montastruc JL. Orthostatic hypotension in patients with Parkinson’s disease: pathophysiology and management. Drugs Aging 2001;18:495–505.
    OpenUrlCrossRefPubMed
  25. ↵
    Allan LM, Ballard CG, Allen J, et al. Autonomic dysfunction in dementia. J Neurol Neurosurg Psychiatry 2007;78:671–677.
    OpenUrlAbstract/FREE Full Text
  26. ↵
    Ludin SM, Steiger UH, Ludin HP. Autonomic disturbances and cardiovascular reflexes in idiopathic Parkinson’s disease. J Neurol 1987;235:10–15.
    OpenUrlCrossRefPubMed
  27. Turkka JT, Tolonen V, Myllyla VV. Cardiovascular reflexes in Parkinson’s disease. Eur Neurol 1987;26:104–112.
    OpenUrlCrossRefPubMed
  28. van Dijk JG, Haan J, Zwinderman K, Kremer B, van Hilten BJ, Roos RA. Autonomic nervous system dysfunction in Parkinson’s disease: relationships with age, medication, duration, and severity. J Neurol Neurosurg Psychiatry 1993;56:1090–1095.
    OpenUrlAbstract/FREE Full Text
  29. ↵
    Piha SJ, Rinne JO, Rinne VK, Seppänen A. Autonomic dysfunction in recent onset and advanced Parkinson’s disease. Clin Neurol Neurosurg 1988;90:221–226.
    OpenUrlCrossRefPubMed
  30. Meco G, Pratesi L, Bonifati V. Cardiovascular reflexes and autonomic dysfunction in Parkinson’s disease. J Neurol 1991;238:195–199.
    OpenUrlCrossRefPubMed
  31. ↵
    Asahina M, Sakakibara R, Liu Z, et al. The raphe magnus/pallidus regulates sweat secretion and skin vasodilation of the cat forepaw pad: a preliminary electrical stimulation study. Neurosci Lett 2007;415:283–287.
    OpenUrlCrossRefPubMed
  32. ↵
    Orimo S, Amino T, Itoh Y, et al. Cardiac sympathetic denervation precedes neuronal loss in the sympathetic ganglia in Lewy body disease. Acta Neuropathol 2005;109:583–588.
    OpenUrlCrossRefPubMed
  33. Suzuki M, Kurita A, Hashimoto M, et al. Impaired myocardial 123I-metaiodobenzylguanidine uptake in Lewy body disease: comparison between dementia with Lewy bodies and Parkinson’s disease. J Neurol Sci 2006;240:15–19.
    OpenUrlPubMed
  34. Minguez-Castellanos A, Chamorro CE, Escamilla-Sevilla F, et al. Do alpha-synuclein aggregates in autonomic plexuses predate Lewy body disorders? A cohort study. Neurology 2007;68:2012–2018.
    OpenUrlAbstract/FREE Full Text
  35. Tsuboi Y, Dickson DW. Dementia with Lewy bodies and Parkinson’s disease with dementia: are they different? Parkinsonism Relat Disord 2005;11:S47–S51.
    OpenUrlCrossRefPubMed
  36. ↵
    Critchley HD. Neural mechanisms of autonomic, affective, and cognitive integration. J Comp Neurol 2005;493:154–166.
    OpenUrlCrossRefPubMed
  37. ↵
    Asahina M, Suzuki A, Mori M, Kanesaka T, Hattori T. Emotional sweating response in a patient with bilateral amygdala damage. Int J Psychophysiol 2003;47:87–93.
    OpenUrlCrossRefPubMed
  38. Boucsein W. Electrodermal Activity. New York: Plenum Press;
  39. ↵
    Vetrugno R, Liguori R, Cortelli P, Montagna P. Sympathetic skin response: basic mechanisms and clinical applications. Clin Auton Res 2003;13:256–270.
    OpenUrlCrossRefPubMed

Disputes & Debates: Rapid online correspondence

No comments have been published for this article.
Comment

REQUIREMENTS

If you are uploading a letter concerning an article:
You must have updated your disclosures within six months: http://submit.neurology.org

Your co-authors must send a completed Publishing Agreement Form to Neurology Staff (not necessary for the lead/corresponding author as the form below will suffice) before you upload your comment.

If you are responding to a comment that was written about an article you originally authored:
You (and co-authors) do not need to fill out forms or check disclosures as author forms are still valid
and apply to letter.

Submission specifications:

  • Submissions must be < 200 words with < 5 references. Reference 1 must be the article on which you are commenting.
  • Submissions should not have more than 5 authors. (Exception: original author replies can include all original authors of the article)
  • Submit only on articles published within 6 months of issue date.
  • Do not be redundant. Read any comments already posted on the article prior to submission.
  • Submitted comments are subject to editing and editor review prior to posting.

More guidelines and information on Disputes & Debates

Compose Comment

More information about text formats

Plain text

  • No HTML tags allowed.
  • Web page addresses and e-mail addresses turn into links automatically.
  • Lines and paragraphs break automatically.
Author Information
NOTE: The first author must also be the corresponding author of the comment.
First or given name, e.g. 'Peter'.
Your last, or family, name, e.g. 'MacMoody'.
Your email address, e.g. higgs-boson@gmail.com
Your role and/or occupation, e.g. 'Orthopedic Surgeon'.
Your organization or institution (if applicable), e.g. 'Royal Free Hospital'.
Publishing Agreement
NOTE: All authors, besides the first/corresponding author, must complete a separate Publishing Agreement Form and provide via email to the editorial office before comments can be posted.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.

Vertical Tabs

You May Also be Interested in

Back to top
  • Article
    • Abstract
    • Glossary
    • METHODS
    • RESULTS
    • DISCUSSION
    • Footnotes
    • REFERENCES
  • Figures & Data
  • Info & Disclosures
Advertisement

Related Articles

  • No related articles found.

Alert Me

  • Alert me when eletters are published
Neurology: 99 (6)

Articles

  • Ahead of Print
  • Current Issue
  • Past Issues
  • Popular Articles
  • Translations

About

  • About the Journals
  • Ethics Policies
  • Editors & Editorial Board
  • Contact Us
  • Advertise

Submit

  • Author Center
  • Submit a Manuscript
  • Information for Reviewers
  • AAN Guidelines
  • Permissions

Subscribers

  • Subscribe
  • Activate a Subscription
  • Sign up for eAlerts
  • RSS Feed
Site Logo
  • Visit neurology Template on Facebook
  • Follow neurology Template on Twitter
  • Visit Neurology on YouTube
  • Neurology
  • Neurology: Clinical Practice
  • Neurology: Genetics
  • Neurology: Neuroimmunology & Neuroinflammation
  • Neurology: Education
  • AAN.com
  • AANnews
  • Continuum
  • Brain & Life
  • Neurology Today

Wolters Kluwer Logo

Neurology | Print ISSN:0028-3878
Online ISSN:1526-632X

© 2022 American Academy of Neurology

  • Privacy Policy
  • Feedback
  • Advertise